※ 引述《Dimitre (迪米崔)》之铭言：
: 1.原文连结：
: ※过长无法点击者必须缩网址
: https://reurl.cc/GVGreD
: 2.原文内容：
: Moderna’s closely watched early-stage human trial for a coronavirus vaccine
: produced Covid-19 antibodies in all 45 participants, the biotech company
: announced Monday.
: Each participant was assigned to receive a 25 microgram, 100 mcg or 250 mcg
: dose, with 15 people in each dose group. Study participants received two
: doses of the potential vaccine via intramuscular injection in the upper arm
: approximately 28 days apart. Data on a second dose was not available for the
: 250 mcg group, the company said.
: At day 43, or two weeks following the second dose, levels of binding
: antibodies in the 25 mcg group were at the levels generally seen in blood
: samples from people who recovered from the disease, the company said.
: Antibodies in the 100 mcg had antibodies that “significantly exceeded levels
: ” in recovered patients.
: The vaccine also produced neutralizing antibodies against Covid-19 in at
: least eight participants, the company said. Four participants were assigned
: to receive a 25 microgram dose, while the other four received 100 mcg. Levels
: of neutralizing antibodies were at or above levels in blood samples, the
: company said. Data on neutralizing antibodies for the other participants were
: not yet available, Moderna said.
: “These interim Phase 1 data, while early, demonstrate that vaccination with
: mRNA-1273 elicits an immune response of the magnitude caused by natural
: infection starting with a dose as low as 25 μg,” Tal Zaks, the chief
: medical officer at Moderna, said in s statement.
: “When combined with the success in preventing viral replication in the lungs
: of a pre-clinical challenge model at a dose that elicited similar levels of
: neutralizing antibodies, these data substantiate our belief that mRNA-1273
: has the potential to prevent COVID-19 disease and advance our ability to
: select a dose for pivotal trials,” Zaks added.
: There are formally approved treatments for Covid-19, which has killed at
: least 315,225 and sickened 4.7 million people worldwide since emerging from
: the Chinese city of Wuhan more than 4 months ago, according to data compiled
: by Johns Hopkins University.
: Moderna has been fast-tracking work with the National Institutes of Health,
: an agency within the Department of Health and Human Services, to develop a
: vaccine.
: The company said the vaccine was generally safe and well tolerated.
: The potential vaccine by Moderna contains genetic material called messenger
: RNA, or mRNA, that was produced in a lab. The mRNA is a genetic code that
: tells cells what to build — in this case, an antigen that may induce an
: immune response for the virus.
: The phase 1 trial took place at the Kaiser Permanente Washington Health
: Research Institute in Seattle, Washington. It tested the vaccine on 45 males
: and non-pregnant females between the ages of 18 and 55.
如果把细菌比喻成敌军, 抗体就是保护身体的军队.
一个正常国家, 只要遭受入侵就会反击 > 这就是产生抗体.
但是抗体有特异性, 只对某种病毒有效. 拿对付一般感冒的抗体打武汉肺炎是没有用的
就像是病毒开坦克近来, 我们让士兵拿50手枪反击, 叮叮当当效果跟BB枪差不多.
应该要找有RPG的抗体过来才对.
回到报导, 这篇报导包含三个讯息
1. 25ug即可引发免疫反应.
这是好消息. 代表只要少量的假想敌就可以让身体产生军队准备抗敌.
2. 100ug剂量产生的的抗体量超过恢复期的量
好消息. 越多假想敌, 身体会制造越多军队.
3. 少部分人有副作用, 但无生命危险.
算好消息吧? 至少还不会自己被假想敌干掉, 尚可接受.
但样本数低, 扩大接踵后未必不会出现致死.
例如: 流感感冒疫苗还是有案例接踵后致死.
这三点代表这个疫苗是可接受的 (但不代表有效)
但这也并不能说是什么重大突破, 毕竟疫苗本该就要触发免疫反应 (促进身体制造军队)
如果没办法, 那不如注射一罐舒跑好了.
以上是这篇新闻所含的讯息
比较重要的应该是这篇新闻内的一段
这是他们自己公司发的
https://investors.modernatx.com/news-releases/news-release-details/
moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine
At this time, neutralizing antibody data are available only for the first
four participants in each of the 25 μg and 100 μg dose level cohorts.
Consistent with the binding antibody data, mRNA-1273 vaccination elicited
neutralizing antibodies in all eight of these participants, as measured by
plaque reduction neutralization (PRNT) assays against live SARS-CoV-2. The
levels of neutralizing antibodies at day 43 were at or above levels generally
seen in convalescent sera.
4. 8个病人有产生可以对付新冠的抗体.
不过他们的意思好像是只做8个取样, 25ug的病人 x4 100ug的病人 x4
8位都有产生可以对付新冠的抗体.
看上去是100%啦
但是用这消息来看是否有效言之过早, 因为检验有没有效是更后面的事情,
有更严格且更可靠的检验.
这边只能说是偷喵看答案. 先给大家闻一下香味, 真香一下. 炒个股票.
有做过研究的都知道, 实验数据常常报喜不报忧. 就算内行人也常常被忽悠得团团转.
现在这个声明来自于自家公司, 也没有任何数据或是实验图片佐证.
到底这个士兵拿的RPG是真的火箭弹, 还是水火箭.
还是要等到第三阶段才知道
目前结果大家听听就好, 不要真以为是解药.
补充: 会叫大家不要相信解药出来了, 是因为这个声明说"有效", 可中和病毒.
但这个在实验中的"有效", 其实是个很大的模糊地带.
就像雅量课文说的, 有人看像稿纸, 有人看像棋盘, 但对我来说它就是块绿豆糕.
妈的绿豆糕这也差太多了吧.
但你又不能说我错, 这是"我的"解读阿.
所以除非论文发出来, 不然就再看看囉.
不过炒股还是可以炒啦
毕竟大家不在乎真相, 只在乎股价.